How can we, humans, look at our relationship to nature differently? In season three of Going Wild, on top of stories about animals, we invite you to journey through the entire ecological web — from the tiniest of life forms to apex predators — alongside the scientists, activists and adventurers who study it. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals in their natural habitats all over the world for years. Our award-winning podcast takes you inside the hidde ...
…
continue reading
Kandungan disediakan oleh Sano Genetics. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Sano Genetics atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
Player FM - Aplikasi Podcast
Pergi ke luar talian dengan aplikasi Player FM !
Pergi ke luar talian dengan aplikasi Player FM !
EP 139: Rare disease breakthroughs using tRNA with Michelle Werner, CEO of Alltrna and CEO-Partner of Flagship Pioneering
MP3•Laman utama episod
Manage episode 424478231 series 2631947
Kandungan disediakan oleh Sano Genetics. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Sano Genetics atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
0:00 Intro to The Genetics Podcast.
01:00 Welcome to Michelle.
02:00 Sstop codon diseases and how are they characterised
03:45 Diseases caused by premature stop codons in haploinsufficient genes.
04:35 The role of transfer RNA technology in finding solutions for premature stop codon diseases.
06:16 How Alltrna is engineering tRNAs which can bind to premature termination codons so healthy coding can be restored.
08:10 The number of different engineered tRNAs required to address the 6,000+ genetic diseases
09:38 How Alltrna aims to deliver precision repair using just 19 amino acids.
12:10 Lipid nanoparticles: Modes of delivery and how to get the technology to the right tissues.
14:20 Major types of delivery, from Adeno-Associated Virus (AVV) to conjugations.
16:30 The development of tRNA as a new therapeutic approach and the latest foundational tools.
18:38 How basket clinical trials in the oncology space are enabling mutation specific therapies.
20:22 Entering into the rare genetic liver disease space with a basket trial approach.
21:40 tRNA opening up a unique opportunity to target multiple rare and ultra-rare diseases.
23:13 Measuring efficacy when using an umbrella approach to stop codon diseases.
26:25 Tackling conversations with the Food and Drug Administration and other health authorities.
29:46 How proving the modality to be safe and effective opens up the possibility to focus on diseases which are less well characterised.
31:18 The importance of patient advocacy groups and industry collaboration for delivering therapies and technologies across different geographies.
32:40 Decision-making, including when to develop inhouse and when to seek external partnerships.
34:42 Key learnings Michelle has brought from large pharma organisations to Alltrna
37:51 Working with patient-led organisations to power development in disease areas where there is less commercial value.
40:21 Why Michelle is so passionate about the work being done at Alltrna and how the tRNA modality can bring new solutions to rare disease families and patients.
41:28 One technology or idea Michelle thinks everyone should keep watching and learn more about.
Please consider rating and reviewing us on your chosen podcast listening platform!
Find out more:
182 episod
MP3•Laman utama episod
Manage episode 424478231 series 2631947
Kandungan disediakan oleh Sano Genetics. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Sano Genetics atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
0:00 Intro to The Genetics Podcast.
01:00 Welcome to Michelle.
02:00 Sstop codon diseases and how are they characterised
03:45 Diseases caused by premature stop codons in haploinsufficient genes.
04:35 The role of transfer RNA technology in finding solutions for premature stop codon diseases.
06:16 How Alltrna is engineering tRNAs which can bind to premature termination codons so healthy coding can be restored.
08:10 The number of different engineered tRNAs required to address the 6,000+ genetic diseases
09:38 How Alltrna aims to deliver precision repair using just 19 amino acids.
12:10 Lipid nanoparticles: Modes of delivery and how to get the technology to the right tissues.
14:20 Major types of delivery, from Adeno-Associated Virus (AVV) to conjugations.
16:30 The development of tRNA as a new therapeutic approach and the latest foundational tools.
18:38 How basket clinical trials in the oncology space are enabling mutation specific therapies.
20:22 Entering into the rare genetic liver disease space with a basket trial approach.
21:40 tRNA opening up a unique opportunity to target multiple rare and ultra-rare diseases.
23:13 Measuring efficacy when using an umbrella approach to stop codon diseases.
26:25 Tackling conversations with the Food and Drug Administration and other health authorities.
29:46 How proving the modality to be safe and effective opens up the possibility to focus on diseases which are less well characterised.
31:18 The importance of patient advocacy groups and industry collaboration for delivering therapies and technologies across different geographies.
32:40 Decision-making, including when to develop inhouse and when to seek external partnerships.
34:42 Key learnings Michelle has brought from large pharma organisations to Alltrna
37:51 Working with patient-led organisations to power development in disease areas where there is less commercial value.
40:21 Why Michelle is so passionate about the work being done at Alltrna and how the tRNA modality can bring new solutions to rare disease families and patients.
41:28 One technology or idea Michelle thinks everyone should keep watching and learn more about.
Please consider rating and reviewing us on your chosen podcast listening platform!
Find out more:
182 episod
Semua episod
×Selamat datang ke Player FM
Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.